OBJECTIVE: To make an open assessment of the efficacy and tolerance of @entity2810 in a population of @entity1 with drug resistant partial @entity410 . @entity1 AND METHODS: We did an open multicentric study, in Spain, in which @entity1 with @entity302 treated with one or more drugs were also given @entity2810 . The main objective of the study was to determine the initial dose and titration of the drug and secondly to evaluate its efficacy and safety. We recorded data on the etiology of the @entity410 , their frequency and type and the occurrence of adverse effects. The study took place over a period of one year during which there were five appointments for consultation (after six weeks, three months, six months, nine months and one year). RESULTS: We initially included 1,010 @entity1 of which 941 fulfilled the selection criteria. The average age was 32.2 years. The aetiology was symptomatic in 45%. 61.7% of the @entity1 had had previous treatment with three or more anti @entity302 drugs. The doses were changed at a rate of 5mg/day per week. The average dose of @entity2810 reached during the maintenance phase was 34mg/day. 9.9% of the @entity1 who were followed up for one year (426) had no @entity410 after the second consultation (when the maintenance dose of @entity2810 was reached). 35% of those who came to their final consultation appointment had had no @entity410 in the previous three months. 81.7% of the @entity1 followed up for a year had an overall reduction in the number of @entity410 of over 50% between the first and last consultations. An over 50% reduction in @entity410 was seen in both those of 12 25 years and the 26 65 years old (75% and 73.1% respectively) whilst 86.7% of the @entity1 aged over 65 years also had this degree of improvement. 48.5% of the @entity1 had some type of adverse effect during the study. Somnolence was the commonest side effect (28.2% of the @entity1 ), followed by dizziness (21.5%). In most cases the adverse effects were transient or mild (tolerable). During the study 104 @entity1 had their treatment with @entity2810 stopped (11.1%) for intolerance and 113 @entity1 (12%) because it was ineffective. No @entity1 had non @entity159 . CONCLUSION: @entity2810 is an effective, well tolerated drug when used as additional treatment in @entity1 with @entity302 .

[An open study of XXXX in @entity302 ].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic', 'partial epilepsy'] @entity159 :: ('MESH:D013226', 'Disease') :: ['convulsive status epilepticus'] @entity2810 :: ('MESH:C059205', 'Chemical') :: ['Tiagabine', 'tiagabine']
@entity2810 :: (MESH:C059205,Chemical) :: ['tiagabine']
